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CONSENSUS
Practical use of dabigatran etexilate for stroke
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SUMMARY
Atrial fibrillation (AF) is associated with an increased risk of thromboembolism,
and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists
(VKAs) have been the standard of care for stroke prevention in patients with AF
since the early 1990s. They are very effective for the prevention of cardioembolic
stroke, but are limited by factors such as drug–drug interactions, food interactions,
slow onset and offset of action, haemorrhage and need for routine anticoagulation
monitoring to maintain a therapeutic international normalised ratio (INR). Multiple
new oral anticoagulants have been developed as potential replacements for VKAs
for stroke prevention in AF. Most are small synthetic molecules that target throm-
bin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban,
betrixaban, YM150). These drugs have predictable pharmacokinetics that allow
fixed dosing without routine laboratory monitoring. Dabigatran etexilate, the first
of these new oral anticoagulants to be approved by the United States Food and
Drug Administration and the European Medicines Agency for stroke prevention in
patients with non-valvular AF, represents an effective and safe alternative to VKAs.
Under the auspices of the Regional Anticoagulation Working Group, a multidisci-
plinary group of experts in thrombosis and haemostasis from Central and Eastern
Europe, an expert panel with expertise in AF convened to discuss practical, clini-
cally important issues related to the long-term use of dabigatran for stroke preven-
tion in non-valvular AF. The practical information reviewed in this article will help
clinicians make appropriate use of this new therapeutic option in daily clinical
practice.
What’s known
Three new oral anticoagulants (the direct thrombin
inhibitor dabigatran etexilate and the direct factor
Xa inhibitors rivaroxaban and apixaban) have
recently been approved for stroke prevention in
atrial fibrillation.
What’s new
Under the auspices of the Regional Anticoagulation
Working Group, an expert panel convened to discuss
practical, clinically important issues related to the
long-term use of dabigatran etexilate for stroke
prevention in non-valvular atrial fibrillation. This
practical information will help clinicians make
appropriate use of this new therapeutic option in
daily clinical practice.
Introduction
Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia. It affects approximately 1–2% of
the world population (1) and its prevalence increases
with age (2). AF is associated with an increased risk of
thromboembolism and is the most prevalent factor
for cardioembolic stroke. Approximately, 15% of all
strokes, and up to one-third of strokes affecting peo-
ple over 80 years of age, occur in patients with AF (3).
Vitamin K antagonists (VKAs) have been the stan-
dard of care for stroke prevention in patients with
AF since the early 1990s. They are very effective for
the prevention of cardioembolic stroke (relative risk
reduction of 64% vs. placebo) (4), but are limited by
factors such as drug–drug interactions, food interac-
tions, slow onset and offset of action, haemorrhage
and need for routine anticoagulation monitoring to
maintain a therapeutic international normalised ratio
(INR) (5). These limitations have resulted in the
underuse of VKAs (6). Even when they are pre-
scribed, the level of anticoagulation with VKAs is fre-
quently outside the therapeutic range, potentially
compromising safety and efficacy (7).
Multiple new oral anticoagulants have been devel-
oped as potential replacements for VKAs for stroke
prevention in AF (8–10). Most are small synthetic
molecules that target thrombin (e.g. dabigatran etexi-
late) or factor Xa (e.g. rivaroxaban, apixaban, edox-
aban, betrixaban, YM150). These drugs have
predictable pharmacokinetics that allow fixed dosing
without routine laboratory monitoring. The pharma-
cological properties of dabigatran etexilate are
described in Table 1 (11). Dabigatran etexilate is cur-
rently approved in many countries, including the
United States, Canada, Japan and the European
Union for stroke prevention in AF. Postmarketing
studies are needed to evaluate the benefits and risks
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of new therapeutic agents in larger and more diverse
populations than those included in randomised con-
trolled trials, and in situations that represent real-
world conditions. The Global Registry on Long-Term
Oral Antithrombotic Treatment in Patients with
Atrial Fibrillation (GLORIA-AF) aims to collect data
on the safety and effectiveness of antithrombotic
treatments, including VKAs and dabigatran etexilate,
in over 50,000 patients with newly diagnosed non-
valvular AF at significant risk for stroke [ClinicalTri-
als.gov identifiers: NCT01428765 (Phase 1) and
NCT01468701 (Phase 2 and 3)].
Under the auspices of the Regional Anticoagula-
tion Working Group, a multidisciplinary group of
experts in thrombosis and haemostasis from Central
and Eastern Europe, an expert panel with expertise
in AF convened to discuss practical, clinically impor-
tant issues related to the long-term use of dabigatran
for stroke prevention in non-valvular AF. Helpful
guidance can also be found in two recent publica-
tions (12,13).
Efficacy and safety of dabigatran
etexilate compared with VKAs and
other novel anticoagulants for stroke
prevention in AF
Dabigatran etexilate in the RE-LY study
Dabigatran etexilate was evaluated for stroke preven-
tion in AF in the Randomised Evaluation of Long-
Term Anticoagulation Therapy (RE-LY) study
(14,15). RE-LY was a randomised non-inferiority
trial designed to compare two fixed doses of dabiga-
tran (110 mg twice daily and 150 mg twice daily),
each administered in a blinded manner, with open-
label use of warfarin adjusted locally to maintain an
INR of 2.0–3.0 [Prospective, Randomised, Open,
Blinded End-point (PROBE) study]. A total of
18,113 patients from 951 centres in 44 countries
were enrolled. Mean age was 71 years and 63.6% of
the patients were men. Half of the patients had
received long-term therapy with VKAs. Mean
CHADS2 [cardiac failure, hypertension, age, diabetes,
stroke (doubled)] score was 2.1 (the proportion of
patients with a CHADS2 score of 0–1, 2 or 3–6 was
31.9%, 35.6% and 32.5%, respectively). The median
duration of the follow-up period was 2.0 years.
In the warfarin group, mean time in therapeutic
range (TTR) was 64%.
The main efficacy and safety results of the RE-LY
study are described in Table 2. Both dabigatran doses
were non-inferior to warfarin with respect to the pri-
mary efficacy outcome of stroke or systemic embo-
lism. In addition, the 150-mg dose was superior to
warfarin with respect to the primary efficacy out-
come and significantly reduced both ischaemic and
haemorrhagic stroke. The 110-mg dose significantly
reduced haemorrhagic stroke only, with comparable
efficacy to warfarin for ischaemic stroke. Myocardial
infarction (MI) rates were similar with dabigatran
and warfarin (see below).
With respect to the primary safety outcome of
major bleeding, both dabigatran doses were non-infe-
rior to warfarin and the 110-mg dose was superior
to warfarin. In addition, the rates of life-threatening
bleeding and intracranial bleeding were significantly
reduced with both doses of dabigatran. The rates of
intracranial haemorrhage were 0.23%/year, 0.32%/
year and 0.76%/year with the 110-mg dose, the 150-
mg dose and warfarin, respectively (p < 0.001).
Intracranial haemorrhage is the most devastating
complication of VKA therapy and a major concern
for clinicians; therefore, the relative risk reduction of
70% with the 110-mg dose and of 59% with the
150-mg dose represents an important advantage of
dabigatran. A significant increase in the risk of gas-
trointestinal bleeding was observed with the 150-mg
dose but not with the 110-mg dose. Dyspepsia
occurred more frequently with both doses of dabiga-
tran than with warfarin (see below).
Two recently published phase III trials have com-
pared the oral direct factor Xa inhibitors rivaroxaban
and apixaban, respectively, with warfarin for primary
stroke prevention in patients with non-valvular AF.
Rivaroxaban in the ROCKET AF study
The Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism
for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation (ROCKET AF) study (16) was a
double-blind, double-dummy trial comparing riva-
roxaban 20 mg once daily (15 mg once daily in
Table 1 Dabigatran etexilate: pharmacological
properties
Oral direct thrombin inhibitor
Double prodrug converted into its active metabolite
dabigatran
Bioavailability: ~ 6%
Time to peak plasma concentration (Cmax): 2 h
Half-life: single dose: 8–10 h; multiple dose: 12–17 h
Binds directly to thrombin with a high affinity and specificity
(reversible inhibition)
Predictable anticoagulant effect (no need for coagulation
monitoring)
Fixed dose
No interactions with food
Low risk of drug–drug interactions
Excreted unchanged via kidneys (85% renal elimination)
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patients with a creatinine clearance between 30 and
49 ml/min) to dose-adjusted warfarin. A total of
14,264 patients from 1178 centres in 45 countries
were randomised. Mean age was 73 years. Mean
CHADS2 score was 3.47 (the proportion of patients
with a CHADS2 score of 2 or 3–6 was 13% and
87%, respectively). In the warfarin group, mean TTR
was 55%.
The main efficacy and safety results of the
ROCKET AF study are described in Table 3. Riva-
roxaban was non-inferior to warfarin with respect to
the primary efficacy outcome (stroke or non-central
nervous system systemic embolism) and the primary
safety outcome (major bleeding). Efficacy was supe-
rior according to the on-treatment analysis but not
according to the intention-to-treat analysis. MI rates
were similar with rivaroxaban and warfarin. Rivarox-
aban significantly reduced haemorrhagic stroke but
not ischaemic stroke. The rates of intracerebral
haemorrhage were 0.8%/year with rivaroxaban and
1.2%/year with warfarin, respectively (p < 0.02).
Rivaroxaban is currently approved in many coun-
tries including the United States, Canada, Japan and
the European Union for stroke prevention in AF.
Apixaban in the ARISTOTLE study
The Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation (ARIS-
TOTLE) trial (17) was a double-blind, double-dummy
trial comparing apixaban 5 mg twice daily (2.5 mg
twice daily in two or more of the following criteria:
age  80 years, body weight  60 kg or serum cre-
atinine  1.5 mg/dl) with adjusted-dose warfarin. A
total of 18,201 patients from 1034 centres in 39 coun-
tries were enrolled. Median age was 70 years and 57%
of the patients had received long-term therapy with
VKAs. Mean CHADS2 score was 2.1 (the proportion
of patients with a CHADS2 score  1, 2 or  3 was
34%, 35.8% and 30.2%, respectively). The median
duration of the follow-up period was 1.8 years. In the
warfarin group, mean TTR was 62%.
The main efficacy and safety results of the ARIS-
TOTLE study are described in Table 4. Apixaban was
superior warfarin with respect to the primary efficacy
outcome (stroke or systemic embolism) and the pri-
mary safety outcome (major bleeding according to
ISTH criteria). In addition, the key efficacy outcome
of all-cause mortality was reduced by 11%
(p < 0.047). MI rates were similar with apixaban and
warfarin. Apixaban significantly reduced haemorrhag-
ic stroke but not ischaemic stroke. The rate of intra-
cranial haemorrhage was 0.33%/year with apixaban
and 0.8%/year with warfarin, respectively (p < 0.001).
Apixaban was recently approved in the European
Union and in the United States for stroke prevention
in AF.
Indirect comparisons of dabigatran etexilate,
rivaroxaban and apixaban for stroke
prevention in atrial fibrillation
Several studies have indirectly compared dabigatran
etexilate (150 mg twice daily and 110 mg twice
daily), rivaroxaban and apixaban for efficacy and
safety outcomes (18,19). Although no profound dif-
ferences in efficacy and safety were reported, some
differences were observed. For example, dabigatran
etexilate 150 mg twice daily was superior to rivarox-
aban for efficacy. Major bleeding was significantly
lower with apixaban than with rivaroxaban or dabig-
atran etexilate 150 mg twice daily. In addition, major
bleeding was significantly lower with dabigatran etex-
ilate 110 mg twice daily than with rivaroxaban.
However, such indirect intertrial comparisons should
be used with caution and head-to-head studies will
Table 2 Main efficacy and safety results of the RE-LY study (14,15)
Dabigatran
110 mg
(N = 6016)
Dabigatran
150 mg
(N = 6076)
Warfarin
(N = 6076)
Dabigatran
110 mg vs. Warfarin
Dabigatran
150 mg vs. Warfarin
Efficacy outcomes (%/year) (%/year) (%/year) RR (p-value*) RR (p-value*)
Stroke or systemic embolism 1.54 1.11 1.71 0.90 (< 0.001†, 0.34) 0.66 (< 0.001†, < 0.001)
Ischaemic or unspecified stroke 1.34 0.92 1.21 1.11 (0.35) 0.76 (0.003)
Haemorrhagic stroke 0.12 0.10 0.38 0.31 (< 0.001) 0.26 (< 0.001)
Myocardial infarction 0.82 0.81 0.64 1.29 (< 0.09) 1.27 (< 0.12)
Safety outcomes (%/year) (%/year) (%/year) RR (p-value) RR (p-value)
Major bleeding 2.87 3.32 3.57 0.80 (0.003) 0.93 (0.31)
Gastrointestinal bleeding 1.15 1.56 1.07 1.08 (< 0.52) 1.48 (< 0.001)
Intracranial bleeding 0.23 0.32 0.76 0.30 (< 0.001) 0.41 (< 0.001)
*p-value for superiority, except otherwise indicated; †p-value for non-inferiority. RR, relative risk.
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be required to confirm any differences in efficacy or
safety between these drugs.
Clinical use of dabigatran etexilate for
stroke prevention in atrial fibrillation
– practical considerations
How to define ‘well-controlled’ VKA therapy?
What are the benefits of dabigatran in ‘well-
controlled’ VKA patients?
A patient who is ‘well controlled’ on VKA therapy is
a patient whose INR fluctuates very little (i.e. is in
the target range most of the time). The TTR, defined
as the estimated total proportion of time that the
INR is within the predetermined target range (INR
2.0–3.0) in an individual patient or in a given clinical
setting, reflects the quality of anticoagulation. The
most commonly used method of calculating the TTR
is the Rosendaal method (20). The well-controlled
patient on VKA therapy may be defined as a patient
with an individual TTR over 70%, who handles VKA
treatment and laboratory monitoring without prob-
lems (21).
In most studies, the TTR refers to clinical centres
and reflects the proportion of patients that these
centres are able to hold permanently in the thera-
peutic range. A strong association between centre-
based TTR and the effectiveness and safety of VKA
therapy has been observed across a large number of
studies (22–25). However, in usual practice the level
of INR control is frequently poor (26,27), and this
should be kept in mind when generalising from the
results of randomised clinical trials. In a systematic
review of 67 studies which included over 50,000
patient receiving VKA therapy for a wide range of
indications, van Walraven et al. found a mean TTR
of 66.4% in randomised controlled trials, 65.6% in
anticoagulation clinics and 56.7% in community
practice (26). Another meta-analysis looking at
patients receiving warfarin therapy for AF in the
United States found a mean TTR of 63% in antico-
agulation clinics vs. 51% in community practice
(28). One of the clear benefits of novel oral antico-
agulants is that they have predictable pharmacoki-
netics allowing fixed dosing without the need for
routine laboratory monitoring.
Table 3 Main efficacy and safety results (intention-to-treat analysis) of the ROCKET AF study (16)
Rivaroxaban (N = 7081) Warfarin (N = 7090) Rivaroxaban vs. Warfarin
Efficacy outcomes (%/year) (%/year) HR (p-value*)
Stroke or systemic embolism 2.1 2.4 0.88 (< 0.001†, 0.12)
Ischaemic stroke 1.34 1.42 0.94 (0.58)
Haemorrhagic stroke 0.26 0.44 0.59 (0.024)
Myocardial infarction 0.91 1.12 0.81 (0.12)
Safety outcomes (%/year) (%/year) RR (p-value)
Major bleeding 3.6 3.4 1.04 (0.58)
Gastrointestinal bleeding 3.15 2.16 (< 0.001)
Intracranial bleeding 0.5 0.7 0.67 (0.02)
*p-value for superiority, except otherwise indicated; †p-value for non-inferiority. HR, hazard ratio; RR, relative risk.
Table 4 Main efficacy and safety results of the ARISTOTLE study (17)
Apixaban (N = 9120) Warfarin (N = 9081) Apixaban vs. Warfarin
Efficacy outcomes (%/year) (%/year) HR (p-value*)
Stroke or systemic embolism 1.27 1.60 0.79 (< 0.01)
Ischaemic stroke or uncertain type of stroke 0.97 1.05 0.92 (0.42)
Haemorrhagic stroke 0.24 0.47 0.51 (< 0.001)
Myocardial infarction 0.53 0.61 0.88 (0.37)
Safety outcomes (%/year) (%/year) RR (p-value)
Major bleeding (ISTH criteria) 2.13 3.09 0.69 (< 0.001)
Gastrointestinal bleeding 0.76 0.86 0.89 (0.37)
Intracranial bleeding 0.33 0.80 0.42 (< 0.001)
*p-value for superiority. HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis.
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A subgroup analysis of the RE-LY trial investigated
the outcomes of the study in relation to each centre’s
mean TTR (cTTR) in warfarin-treated patients (29).
The quartiles of cTTR for patients in the warfarin
group were as follows: less than 57.1%, 57.1–65.5%,
65.5–72.6%, and greater than 72.6%. Mean cTTR
ranged from 44% to 77% (country distribution of
mean TTR is shown on Figure 1). There were no sig-
nificant interactions between cTTR and prevention
of stroke and systemic embolism with either dabiga-
tran dose vs. warfarin. There was a significant inter-
action between cTTR and major bleeding when
comparing the 150-mg dose of dabigatran with war-
farin, with less bleeding events at lower cTTR but a
similar event rate at higher cTTR, whereas rates of
major bleeding were lower with the 110-mg dose of
dabigatran than with warfarin irrespective of cTTR.
The benefits of the 150-mg dose at reducing stroke
and the 110-mg dose at reducing major bleeding vs.
warfarin were consistent irrespective of centres’ qual-
ity of INR control. The rates of intracranial bleeding
were consistently lower in both dabigatran groups
than in the warfarin group irrespective of cTTR. The
benefits of dabigatran are primarily related with the
fact that even compared with well-controlled warfa-
rin therapy dabigatran reduces the risk of intracranial
haemorrhage.
In VKA-treated patients, stability of the antico-
agulant effect is often not achieved for several
weeks after treatment initiation, and as a conse-
quence the risks of stroke and bleeding are highest
during this initial period (30). It is therefore
important to include a significant proportion of
VKA-na€ıve patients in trials comparing VKA ther-
apy and new anticoagulants for stroke prevention
in AF. The RE-LY trial was designed to enrol an
equal proportion of VKA-na€ıve and VKA-experi-
enced patients (31). Within assigned treatment
groups, the only significant differences between
VKA-na€ıve and VKA-experienced patients were
observed in the dabigatran 110 mg group: cardio-
vascular death and the composite outcome of life-
threatening bleeding, disabling stroke and death
were less frequent in VKA-experienced patients.
Previous VKA exposure did not influence the ben-
efits of dabigatran etexilate at either dose compared
with VKA therapy.
Which patients are suitable for dabigatran?
Which factors should be considered when
selecting the dose for an individual patient?
Setting aside cost/reimbursement issues, most
patients with AF requiring anticoagulant therapy
would be suitable for dabigatran. Two compelling
arguments to support the use of dabigatran in most
patients are the superior efficacy of the 150-mg dose
and the two-third reduction in intracerebral haemor-
rhage with both doses. An additional advantage of
dabigatran over VKA therapy is that it does not
require routine coagulation monitoring. Should
financial constraints be considered, priority targets
for dabigatran may be newly diagnosed patients,
patients who are intolerant to VKA therapy, poorly
controlled patients on VKA therapy, patients refusing
VKA therapy and patients with previous stroke or
developing thromboembolic events while on VKA
therapy.
The dosage of dabigatran can be selected based on
patient characteristics considering the superior effi-
cacy of the 150-mg dose and the superior safety of
the 110-mg dose. Clinicians are generally concerned
about drug safety and may be tempted to use the
lower dose. However, as a result of its superior effi-
cacy, the higher dose should be strongly considered
in the absence of specific risk factors for bleeding.
Factors that may contribute to selecting the lower
dabigatran dose include the thromboembolic risk,
any risk of bleeding, drug interactions, age and mod-
Figure 1 Country distribution of mean TTR in the RE-LY trial (29)
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erate renal impairment (CrCl 30–50 ml/min). In
patients with severe renal impairment (CrCl
< 30 ml/min), treatment with dabigatran is contrain-
dicated. Renal function should always be assessed
prior to treatment initiation with dabigatran etexi-
late. During treatment, renal function should be
assessed in clinical situations where it is suspected
that it could decline or deteriorate. In patients with
moderate renal impairment and in those over
75 years of age, renal function should be assessed at
least once a year.
The RE-LY trial included 7258 patients aged
 75 years and 3505 patients with moderate renal
impairment (severe renal impairment was one of
the exclusion criteria) (32). For the primary efficacy
outcome of stroke or systemic embolism, there was
no significant interaction between age or baseline
renal function and dabigatran treatment. Rates of
major bleeding increased with age and there was a
significant interaction between age and treatment
that attenuated the benefits of dabigatran with
increasing age. For patients aged < 75 years, both
doses of dabigatran reduced the risk of major
bleeding compared with warfarin. In patients aged
 75 years, the rate of major bleeding was similar
with dabigatran 110 mg twice daily compared with
warfarin, whereas a trend towards a higher risk of
major bleeding was observed with dabigatran
150 mg twice daily (33). An interaction between
renal function and treatment was no longer evident
after adjustment for age. There was no interaction
between either age or renal function and the bene-
fits of dabigatran vs. warfarin in reducing haemor-
rhagic stroke. The benefit of dabigatran vs. warfarin
for stroke prevention is independent of age and
renal function. The benefit of dabigatran vs. warfa-
rin in reducing extracranial bleeding is significantly
attenuated with increasing age, whereas the reduc-
tion in haemorrhagic stroke is maintained in older
patients.
Patients aged  80 years and patients treated
concomitantly with dabigatran and verapamil
should be treated with the lower dose of dabiga-
tran. In patients aged between 75 and 80 years, the
highest dose should be used; however, the lower
dose can be individually considered, at the discre-
tion of the physician, when the thromboembolic
risk is low and the bleeding risk is high. For
patients with gastritis, oesophagitis or gastroesopha-
geal reflux, the lower dose may be considered. In
patients with moderate renal impairment (CrCl 30–
50 ml/min), the recommended dose is 150 mg
twice daily; however, the lower dose should be
considered in patients with a high risk of bleeding
(13).
What are the main clinically relevant
interactions between dabigatran etexilate and
other drugs?
Dabigatran has a low potential for interactions with
other drugs. It does not interact with the cytochrome
P450 system. As the prodrug dabigatran etexilate is a
substrate of the P-glycoprotein (P-gp) efflux trans-
porter, the main clinically relevant interactions are
with drugs that are strong inhibitors or inducers of
P-gp (13,21). The main clinically relevant drug inter-
actions are listed in Table 5. Concomitant adminis-
tration of atorvastatin, diclofenac, pantoprazole,
clopidogrel and digoxin is possible without dose
adjustment (13).
Caution is recommended when considering con-
comitant prescription of dabigatran etexilate and
non-steroidal anti-inflammatory drugs, antiplatelet
agents, selective serotonin reuptake inhibitors or
serotonin–norepinephrine reuptake inhibitors.
Table 5 Main clinically relevant interactions between
dabigatran etexilate and other drugs (13)
P-glycoprotein
inhibitors
Ketoconazole
(systemic)
Cyclosporine
Itraconazole
Tacrolimus
Dronedarone
Concomitant
administration
is contraindicated
Posaconazole Concomitant
administration is not
recommended
Amiodarone
Quinidine
Concomitant
administration
requires caution and
bleeding risk
assessment
Verapamil Concomitant
administration
requires caution,
bleeding risk
assessment and
dabigatran dose
adjustment (110 mg
twice daily)
P-glycoprotein
inducers
Rifampicin
St. John’s Wort
(Hypericum
perforatum)
Carbamazepine
Phenytoin
Concomitant
administration
should be avoided
Other drugs
interacting with
P-glycoprotein
Protease inhibitors
(e.g. ritonavir,
tipranavir,
nelfinavir,
saquinavir)
Concomitant
administration is not
recommended
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Co-administration of a proton pump inhibitor is
unlikely to reduce the anticoagulant effect of dabiga-
tran etexilate.
How would you manage a dabigatran-treated
patient with acute coronary syndrome? How to
manage an AF patient if coronary intervention
with stent implantation is necessary?
Acute coronary syndromes occurring in patients on
dabigatran therapy should be diagnosed and treated
with early angiography and intervention. Dabigatran
is generally discontinued temporarily during the
acute phase, although an uninterrupted anticoagula-
tion strategy may be preferred in moderate- to high-
risk patients (34).
Following percutaneous coronary intervention
(PCI) with stenting, dual antiplatelet therapy (aspirin
and clopidogrel) is mandatory, and in patients with
AF triple therapy combining dual antiplatelet therapy
and oral anticoagulation should be used (34).
Concomitant administration of a VKA and one or
two antiplatelet agents is associated with a substantial
increased risk of major bleeding events compared
with monotherapy (35–37). However, oral anticoagu-
lant therapy improves prognosis (reduced mortality
and major adverse cardiac events) despite the
increase in major bleeding, even in patients with a
high bleeding risk (38). In patients treated with war-
farin or either dose of dabigatran in the RE-LY trial,
concomitant treatment with aspirin, clopidogrel or
both was associated with increased major bleeding
rates (33). Among, approximately, 1000 patients who
received concomitant treatment with both aspirin
and clopidogrel, the rates of major bleeding were
4.72%, 4.66% and 5.21% in the groups receiving
dabigatran 110 mg twice daily, dabigatran 150 mg
twice daily and warfarin, respectively (33). During
the period when triple therapy is used, the lower
dose of dabigatran (110 mg twice daily) would
appear to be appropriate, in line with the recommen-
dation by recent European and North American con-
sensus documents to maintain an INR at the lower
end of the therapeutic range (2.0–2.5) in VKA-trea-
ted patients (39,40). Both consensus documents
emphasise that limiting the duration of triple therapy
when possible is a key step to reduce the bleeding
risk. However, North American experts recommend
a much longer duration of triple therapy than Euro-
pean experts as they place greater emphasis on
reducing the risk of thrombosis. Both documents
recommend the use of bare metal stents rather than
drug eluting stent in patients with increased bleeding
risk (41). Further studies are needed to evaluate the
efficacy and safety of dabigatran in combination with
dual antiplatelet therapy.
Was there a difference in the rate of MI with
dabigatran compared with VKAs in the RE-LY
study?
In the original report of the RE-LY study, the rate of
MI was significantly higher with both doses of dabig-
atran than with warfarin (14). However, a subse-
quent analysis performed following discussion with
the FDA, which included additional data on silent
MIs (based on the new appearance of pathologic Q
waves on ECG), did not reveal significant differences
between dabigatran and warfarin (15). A detailed
post hoc analysis of the RE-LY study aimed to pro-
vide a better understanding of the effects of dabiga-
tran on myocardial ischaemic events was recently
published (42). This analysis reported rates of MI
and other clinical events related to myocardial
ischaemia: unstable angina, cardiac death, cardiac
arrest, coronary artery bypass graft (CABG) surgery
and PCI. A non-significantly higher number of MIs
was observed with both doses of dabigatran com-
pared with warfarin; there was no excess of other
myocardial ischaemic events. The composite of
stroke, systemic embolism, MI, unstable angina, car-
diac death, cardiac arrest, CABG, PCI and major
bleeding occurred less frequently with dabigatran
than with warfarin (the difference was statistically
significant for the 150-mg dose).
A meta-analysis evaluated the risk of MI or acute
coronary syndrome (ACS) in seven randomised con-
trolled trials comparing dabigatran with warfarin, en-
oxaparin or placebo for stroke prevention in AF,
VTE prevention in major orthopaedic surgery, VTE
treatment and prevention of cardiovascular events in
patients with ACS (43). The RE-LY study accounted
for 59% of the patients and 74% of the events
included in the meta-analysis. The risk of MI or ACS
was found to be increased with dabigatran compared
with the various control treatments. Although the
relative risk increase was 33%, the absolute risk
increase was very small (0.27%). In the six studies
reporting on mortality, overall mortality was signifi-
cantly lower with dabigatran compared with control
treatments.
Warfarin has been shown to be very effective in
preventing reinfarction in patients with previous MI
(44,45). Therefore, the most plausible explanation for
the relative increase in acute coronary events with
dabigatran compared with warfarin is not that dabig-
atran causes coronary events but rather that warfarin
may provide a greater coronary protective effect in
high-risk patients (46,47).
The 2012 focused update of the European Society
of Cardiology for the management of AF state that
in a dabigatran-treated patient presenting with an
acute coronary syndrome, the concerned clinician
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may consider the use of a VKA or a factor Xa inhibi-
tor, although there is little evidence to support this
approach (48). In the RE-LY study, 5650 patients
had a history of coronary artery disease (CAD) and/
or previous MI. The effects of dabigatran etexilate
compared with warfarin were highly consistent
between patients with and without prior CAD and/
or MI (42).
How to manage a dabigatran-treated patient
who presents with an ischaemic stroke?
A patient treated with dabigatran etexilate may
develop an acute ischaemic stroke. Clinical experience
with the use of thrombolytic therapy in patients trea-
ted with dabigatran is very limited: only isolated case
reports have been published (49–54). If the patient’s
activated partial thromboplastin time (aPTT) is pro-
longed, it should be assumed that the patient is antico-
agulated and intravenous administration of
recombinant tissue plasminogen activator should not
be performed (48). The thrombin clotting time (TT)
and the ecarin clotting time (ECT), but not the INR,
are also appropriate tests to assess coagulation status
in dabigatran-treated patients who are considered pos-
sible candidates for thrombolysis (see below) (13).
Until more evidence is available, it appears reason-
able to resume treatment with dabigatran etexilate
immediately after a transient ischaemic attack, 3–
5 days after a minor or moderately severe stroke,
and 10–14 days after a severe stroke (55).
How to use dabigatran in patients undergoing
electrical or pharmacological cardioversion?
Cardioversion (both electric and pharmacological)
in patients with AF is associated with an increased
risk of thromboembolic events. In the RE-LY study,
cardioversion on randomised treatment was permit-
ted. The study protocol recommended maintenance
of the assigned study drug during cardioversion.
As a safety measure, transoesophageal echocardiog-
raphy (TEE) was encouraged. All patients who
underwent cardioversion during their participation
in the RE-LY trial were included in a subgroup
analysis (56). A total of 1983 cardioversions were
performed in 1270 patients during the course of the
trial. TEE was used only in a minority of proce-
dures (165/647 in the dabigatran 110-mg group,
162/672 in the dabigatran 150-mg group and 88/664
in the warfarin group). The rates of stroke and
major bleeding within 30 days of cardioversion on
both doses of dabigatran were low and comparable
to those on warfarin with or without TEE. Based
on the available data, it appears safe to continue
treatment with dabigatran etexilate in patients
undergoing cardioversion.
How should twice-daily dosing be considered
in relation to the benefits in efficacy and
safety seen with dabigatran etexilate?
The twice-daily dosing of dabigatran may be one of
the reasons why dabigatran has been demonstrated
to improve efficacy and safety compared with warfa-
rin. Pharmacokinetic simulations show that a twice-
daily regimen results in less daily fluctuations in
plasma concentrations of dabigatran, thereby mini-
mising the risks of both thrombosis and bleeding
(57). On the other hand, twice-daily dosing may be
a disadvantage with regard to treatment adherence.
A systematic review evaluating the effect of medica-
tion dosing frequency on adherence in chronic dis-
eases found that patients receiving once-daily dosing
had 2–44% more adherent days compared with
patients receiving twice-daily dosing, with most stud-
ies clustering around 13–26% (58). Long-term rates
of compliance with prophylactic therapies in patients
who have no symptoms are usually problematic, and
therefore clinicians need to carefully monitor the
compliance of patients treated with dabigatran.
A conceptual model of adherence to oral anticoagu-
lants in patients with AF was recently developed
based on a literature review and patient focus groups
(59). This model identifies an adherence process that
may guide interventions, such as educational and
behavioural programmes, aimed at improving adher-
ence to anticoagulation therapy.
How to manage dabigatran-treated patients
who develop dyspepsia?
In the RE-LY study, there was a significantly
increased risk of developing dyspepsia with both
doses of dabigatran compared with warfarin (11.8%
with dabigatran 150 mg twice daily, 11.3% with
dabigatran 110 mg twice daily and 5.8% with warfa-
rin; p < 0.001) (14). This adverse event may be
linked to the tartaric acid core of dabigatran cap-
sules (low pH enhances the absorption of the drug).
Although there was a statistically significant increase
in the rate of gastrointestinal bleeding with the 150-
mg dose of dabigatran compared with warfarin
(relative risk, 1.48; p < 0.001) – no difference was
observed with the 110-mg dose of dabigatran (rela-
tive risk, 1.08; p = 0.52) – there is no established
link between dyspepsia and the risk of gastrointesti-
nal bleeding.
Based on limited clinical experience, it may be
beneficial to take dabigatran with meals or a large
glass of water. Sucralfate or drugs that increase gas-
tric pH (antacids, proton pump inhibitors) may be
helpful. If dyspepsia is significant and cannot
be explained by other reasons, the patient may be
switched to an alternative treatment.
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How to manage major bleeding in patients
treated with dabigatran? How to antagonise
the anticoagulant effect of dabigatran?
The management of bleeding in patients on dabiga-
tran therapy should be focused on treatment discon-
tinuation and supportive measures. There is
currently no specific antidote to dabigatran (60);
however, an antidote is currently being developed.
The source of bleeding should be identified and
management should be tailored according the sever-
ity and location of the haemorrhage. Importantly,
diuresis should be maintained, since dabigatran is
excreted via the kidneys. Plasma levels of dabigatran
decrease relatively quickly in patients with normal
renal function because of its relatively short half-life,
and the bleeding risk 12 h after the last dose should
be acceptably low. Meanwhile, supportive measures
to control the bleeding should be taken. In case of
severe or life-threatening haemorrhage, haemodialysis
may be considered, dabigatran being dialysable
because of its relatively low plasma protein binding
(60). The use of reversal agents such as recombinant
activated factor VII or prothrombin complex concen-
trates may be an option, although their utility and
benefit-risk ratio have not been established (60,61).
How to proceed in a dabigatran-treated AF
patient who requires an invasive or surgical
procedure?
In patients who require elective surgery, dabigatran
should be discontinued. The timing of discontinuation
will depend on the complexity of the surgery, the risk
of bleeding and the patient’s renal function (Table 6).
If renal function is normal, plasma levels will
decrease to approximately 25% of steady-state levels
24 h after discontinuation, approximately 12–15%
after 36 h and approximately 5–10% after 48 h.
Patients with moderate renal impairment will require
a longer period of discontinuation prior to surgery.
In these patients, it is important to assess the coagu-
lation status prior to surgery.
If an acute intervention is required, dabigatran
should be temporarily discontinued. If possible, the
invasive or surgical procedure should be delayed
until at least 12 h after the last dose. If the interven-
tion cannot be delayed, the risk of bleeding should
be weighed against the urgency of the procedure.
In contrast to patients on VKA therapy, dabigatran-
treated patients do not require bridging therapy with
low-molecular-weight heparin because of the rapid
onset and offset of action of dabigatran etexilate (48).
Experience with dabigatran etexilate for periproce-
dural anticoagulation in patients undergoing AF
ablation is limited (62–64). Lakkireddy et al.
reported that dabigatran use (with treatment inter-
ruption on the morning of the procedure) was asso-
ciated with more thromboembolic and bleeding
complications compared with uninterrupted warfarin
therapy (62). Using a similar protocol in patients
treated with dabigatran 110 mg twice daily, Kaseno
et al. observed no symptomatic thromboembolic
complications and less bleeding complications than
with warfarin (63). Winkle et al. discontinued dabig-
atran between 36 and 60 h before the procedure
depending on estimated glomerular filtration rate
and observed no bleeding and thromboembolic com-
plications until 30 days after the procedure (64).
Recent guidelines recommend performing catheter
ablation on uninterrupted anticoagulation in AF
patients on VKA therapy (48,65). Studies are
required to evaluate the efficacy and safety of this
approach in dabigatran-treated patients.
What can be recommended with regard to
laboratory monitoring for dabigatran in
exceptional situations?
Dabigatran has a predictable pharmacokinetic profile
which avoids the need for routine coagulation moni-
toring. However, in specific clinical circumstances
(e.g. suspected overdose, dabigatran-treated patients
presenting in emergency departments), it may be
advisable to assess the anticoagulant status of the
patient (60,66).
The TT assay directly assesses the activity of throm-
bin in a plasma sample and allows measurement of the
activity of the direct thrombin inhibitors. TT tests are
available in many hospital laboratories.
TT is well correlated with dabigatran concentra-
tions. The actual TT test measure will depend on the
coagulometer and on the thrombin lot used for the
measurement. It is therefore advisable to use the cali-
brated Hemoclot Thrombin Inhibitor assay (Hyphen
BioMed, Neuville-sur-Oise, France) with direct
calibration with stable, lyophilised dabigatran stan-
dards to calculate the dabigatran concentration rather
than to determine TT only.
Table 6 Dabigatran etexilate discontinuation rules
before invasive or surgical procedures
Renal
function
(CrCl, ml/
min)
Estimated
half-life
(h)
Timing of dabigatran
discontinuation
High risk of
bleeding or
major surgery Standard risk
 80 ~ 13 2 days before 24 h before
50–80 ~ 15 2–3 days before 1–2 days before
30–50 ~ 18 4 days before 2–3 days before
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The aPTT targets the intrinsic pathway of the
coagulation cascade. Prolongation of the aPTT
occurs when dabigatran plasma concentrations
increase, but the aPTT concentration response curve
is curvilinear and flattens at higher concentrations.
The aPTT may be useful in determining an excess of
anticoagulant activity.
Prothrombin time (PT) and the INR represent the
clotting time in the extrinsic coagulation pathway.
Dabigatran has little effect on PT and INR at clini-
cally relevant plasma concentrations. Therefore, INR
tests should not be performed.
The activated clotting time (ACT) is a quantitative
assay based on a similar test principle to aPTT. It is
frequently used as a bedside assay to measure the
anticoagulant effect of unfractionated heparin in
patients undergoing PCI or CABG surgery. There are
limited data for ACT with dabigatran.
The ECT is a specific assay for thrombin genera-
tion; it provides a direct measure of the activity of
direct thrombin inhibitors. There is a close linear
correlation between ECT prolongation and plasma
concentrations of dabigatran. So far the ECT has
been used as a research tool with limited access. The
development of commercial kits may improve the
availability and practicality of this test.
In summary, PT is not an appropriate test to assess
the anticoagulant effect of dabigatran; aPTT is helpful
to detect the presence of dabigatran but not to evalu-
ate its concentration; the Hemoclot Thrombin
Inhibitor test and the ECT are sensitive tests for quan-
titating the anticoagulant effect of dabigatran.
Conclusion
Vitamin K antagonists have been shown to be highly
effective for stroke prevention in patients with AF.
However, their well-known limitations, which
include interactions with numerous foods and drugs
as well as the need for frequent coagulation monitor-
ing and dose adjustments, have resulted in both
underuse and suboptimal use. The development of
new oral anticoagulant agents that have been shown
to be at least as effective as VKAs with a lower bleed-
ing risk, no food interactions, few drug interactions
and no requirement for routine laboratory monitor-
ing, open a new era in the prevention of thrombo-
embolic events in patients with AF. Dabigatran
etexilate, the first of these new oral anticoagulants to
be approved by the United States Food and Drug
Administration and the European Medicines Agency
in this indication, represents an effective and safe
alternative to VKAs. The practical information
reviewed in this article will help clinicians make
appropriate use of this new therapeutic option in
daily clinical practice.
Funding
Financial support for the organization of an expert
meeting and a video conference during which the
authors discussed the content of this article was pro-
vided by Boehringer Ingelheim Regional Centre
Vienna.
References
1 Stewart S, Hart CL, Hole DJ, McMurray JJ. Popu-
lation prevalence, incidence, and predictors of atrial
fibrillation in the Renfrew/Paisley study. Heart
2001; 86: 516–21.
2 Heeringa J, van der Kuip DA, Hofman A et al. Preva-
lence, incidence and lifetime risk of atrial fibrillation:
the Rotterdam study. Eur Heart J 2006; 27: 949–53.
3 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation:
a major contributor to stroke in the elderly. The Fra-
mingham study. Arch Intern Med 1987; 147: 1561–4.
4 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: an-
tithrombotic therapy to prevent stroke in patients
who have nonvalvular atrial fibrillation. Ann Intern
Med 2007; 146: 857–67.
5 Lee A, Crowther M. Practical issues with vitamin K
antagonists: elevated INRs, low time-in-therapeutic
range, and warfarin failure. J Thromb Thrombolysis
2011; 31: 249–58.
6 Ogilvie IM, Newton N, Welner SA et al. Underuse
of oral anticoagulants in atrial fibrillation: a
systematic review. Am J Med 2010; 123: e4.
7 Weitz JI. Meeting the unmet needs in anticoagulant
therapy. Eur J Haematol 2010; 85 (Suppl. 72): 1–28.
8 Schirmer SH, Baumhakel M, Neuberger HR et al.
Novel anticoagulants for stroke prevention in atrial
fibrillation: current clinical evidence and future
developments. J Am Coll Cardiol 2010; 56: 2067–76.
9 Sobieraj-Teague M, O’Donnell M, Eikelboom J.
New anticoagulants for atrial fibrillation. Semin
Thromb Hemost 2009; 35: 515–24.
10 Cabral KP, Ansell J, Hylek EM. Future directions
of stroke prevention in atrial fibrillation: the poten-
tial impact of novel anticoagulants and stroke risk
stratification. J Thromb Haemost 2011; 9: 441–9.
11 Stangier J. Clinical pharmacokinetics and pharma-
codynamics of the oral direct thrombin inhibitor
dabigatran etexilate. Clin Pharmacokinet 2008; 47:
285–95.
12 Pengo V, Crippa L, Falanga A et al. Questions and
answers on the use of dabigatran and perspectives
on the use of other new oral anticoagulants in
patients with atrial fibrillation. A consensus docu-
ment of the Italian Federation of Thrombosis Cen-
ters (FCSA). Thromb Haemost 2011; 106: 868–76.
13 Huisman MV, Lip GY, Diener HC et al. Dabiga-
tran etexilate for stroke prevention in patients with
atrial fibrillation: resolving uncertainties in routine
practice. Thromb Haemost 2012; 107: 838–47.
14 Connolly SJ, Ezekowitz MD, Yusuf S et al.
Dabigatran versus warfarin in patients with
atrial fibrillation. N Engl J Med 2009; 361:
1139–51.
15 Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly
identified events in the RE-LY trial. N Engl J Med
2010; 363: 1875–6.
16 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban
versus warfarin in nonvalvular atrial fibrillation. N
Engl J Med 2011; 365: 883–91.
17 Granger CB, Alexander JH, McMurray JJ et al.
Apixaban versus warfarin in patients with atrial
fibrillation. N Engl J Med 2011; 365: 981–92.
18 Lip GY, Larsen TB, Skjoth F, Rasmussen LH. Indi-
rect comparisons of new oral anticoagulant drugs
for efficacy and safety when used for stroke preven-
tion in atrial fibrillation. J Am Coll Cardiol 2012;
60: 738–46.
19 Mantha S, Ansell J. An indirect comparison of
dabigatran, rivaroxaban and apixaban for atrial
fibrillation. Thromb Haemost 2012; 108: 476–84.
20 Rosendaal FR, Cannegieter SC, van der Meer FJ,
Briet E. A method to determine the optimal inten-
sity of oral anticoagulant therapy. Thromb Haemost
1993; 69: 236–9.
21 De Caterina R, Husted S, Wallentin L et al. New oral
anticoagulants in atrial fibrillation and acute coronary
syndromes: ESC Working Group on Thrombosis-
Task Force on Anticoagulants in Heart Disease posi-
tion paper. J Am Coll Cardiol 2012; 59: 1413–25.
ª 2013 John Wiley & Sons Ltd
Int J Clin Pract, June 2013, 67, 6, 516–526
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation 525
22 Reynolds MW, Fahrbach K, Hauch O et al. Warfa-
rin anticoagulation and outcomes in patients with
atrial fibrillation: a systematic review and metaanal-
ysis. Chest 2004; 126: 1938–45.
23 Jones M, McEwan P, Morgan CL et al. Evaluation
of the pattern of treatment, level of anticoagulation
control, and outcome of treatment with warfarin in
patients with non-valvar atrial fibrillation: a record
linkage study in a large British population. Heart
2005; 91: 472–7.
24 White HD, Gruber M, Feyzi J et al. Comparison of
outcomes among patients randomized to warfarin
therapy according to anticoagulant control: results
from SPORTIF III and V. Arch Intern Med 2007;
167: 239–45.
25 Connolly SJ, Pogue J, Eikelboom J et al. Benefit of
oral anticoagulant over antiplatelet therapy in atrial
fibrillation depends on the quality of international
normalized ratio control achieved by centers and
countries as measured by time in therapeutic range.
Circulation 2008; 118: 2029–37.
26 van Walraven C, Jennings A, Oake N et al. Effect of
study setting on anticoagulation control: a systematic
review and metaregression. Chest 2006; 129: 1155–66.
27 Melamed OC, Horowitz G, Elhayany A, Vinker S.
Quality of anticoagulation control among patients with
atrial fibrillation. Am J Manag Care 2011; 17: 232–7.
28 Baker WL, Cios DA, Sander SD, Coleman CI.
Meta-analysis to assess the quality of warfarin con-
trol in atrial fibrillation patients in the United
States. J Manag Care Pharm 2009; 15: 244–52.
29 Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy
and safety of dabigatran compared with warfarin at
different levels of international normalised ratio
control for stroke prevention in atrial fibrillation:
an analysis of the RE-LY trial. Lancet 2010; 376:
975–83.
30 Garcia DA, Lopes RD, Hylek EM. New-onset atrial
fibrillation and warfarin initiation: high risk peri-
ods and implications for new antithrombotic drugs.
Thromb Haemost 2010; 104: 1099–105.
31 Ezekowitz MD, Wallentin L, Connolly SJ et al.
Dabigatran and warfarin in vitamin K antagonist-
naive and -experienced cohorts with atrial fibrilla-
tion. Circulation 2010; 122: 2246–53.
32 Healey JS, Eikelboom J, Wallentin L et al. Effect of
age and renal function on the risks of stroke and
major bleeding with dabigatran compared to warfa-
rin: an analysis from the RE-LY study. J Am Coll
Cardiol 2010; 55: A4. E37.
33 Eikelboom JW, Wallentin L, Connolly SJ et al. Risk
of bleeding with 2 doses of dabigatran compared
with warfarin in older and younger patients with
atrial fibrillation: an analysis of the randomized
evaluation of long-term anticoagulant therapy
(RE-LY) trial. Circulation 2011; 123: 2363–72.
34 Camm AJ, Kirchhof P, Lip GY et al. Guidelines for
the management of atrial fibrillation: the Task
Force for the Management of Atrial Fibrillation of
the European Society of Cardiology (ESC). Eur
Heart J 2010; 31: 2369–429.
35 Husted SE, Ziegler BK, Kher A. Long-term antico-
agulant therapy in patients with coronary artery
disease. Eur Heart J 2006; 27: 913–9.
36 Hansen ML, Sorensen R, Clausen MT et al. Risk of
bleeding with single, dual, or triple therapy with war-
farin, aspirin, and clopidogrel in patients with atrial
fibrillation. Arch Intern Med 2010; 170: 1433–41.
37 Fisher M, Loscalzo J. The perils of combination an-
tithrombotic therapy and potential resolutions.
Stroke 2011; 42: 278–81.
38 Ruiz-Nodar JM, Marin F, Roldan V et al. Should
we recommend oral anticoagulation therapy in
patients with atrial fibrillation undergoing coronary
artery stenting with a high HAS-BLED bleeding
risk score? Circ Cardiovasc Interv 2012; 5: 459–66.
39 Lip GY, Huber K, Andreotti F et al. Management of
antithrombotic therapy in atrial fibrillation patients
presenting with acute coronary syndrome and/or
undergoing percutaneous coronary intervention/
stenting. Thromb Haemost 2010; 103: 13–28.
40 Faxon DP, Eikelboom JW, Berger PB et al. Consen-
sus document: antithrombotic therapy in patients
with atrial fibrillation undergoing coronary stent-
ing. A North-American perspective. Thromb Hae-
most 2011; 106: 572–84.
41 Huber K, Airaksinen KJ, Cuisset T et al. Anti-
thrombotic therapy in patients with atrial fibrilla-
tion undergoing coronary stenting: similarities and
dissimilarities between North America and Europe.
Thromb Haemost 2011; 106: 569–71.
42 Hohnloser SH, Oldgren J, Yang S et al. Myocardial
ischemic events in patients with atrial fibrillation
treated with dabigatran or warfarin in the RE-LY
(Randomized Evaluation of Long-Term Anticoagu-
lation Therapy) trial. Circulation 2012; 125: 669–76.
43 Uchino K, Hernandez AV. Dabigatran association
with higher risk of acute coronary events: meta-
analysis of noninferiority randomized controlled
trials. Arch Intern Med 2012; 172: 397–402.
44 Smith P, Arnesen H, Holme I. The effect of warfa-
rin on mortality and reinfarction after myocardial
infarction. N Engl J Med 1990; 323: 147–52.
45 Hurlen M, Abdelnoor M, Smith P et al. Warfarin,
aspirin, or both after myocardial infarction. N Engl
J Med 2002; 347: 969–74.
46 Lip GY, Lane DA. Does warfarin for stroke throm-
boprophylaxis protect against MI in atrial fibrilla-
tion patients? Am J Med 2010; 123: 785–9.
47 Eikelboom JW, Weitz JI. Anticoagulation therapy:
dabigatran and risk of myocardial infarction. Nat
Rev Cardiol 2012; 9: 260–2.
48 Camm AJ, Lip GY, De Caterina R et al. 2012
focused update of the ESC Guidelines for the man-
agement of atrial fibrillation: an update of the 2010
ESC Guidelines for the management of atrial fibril-
lation. Developed with the special contribution of
the European Heart Rhythm Association. Eur Heart
J 2012; 33: 2719–47.
49 Chong CA, Chiu L. Dabigatran and acute stroke
thrombolysis. Cerebrovasc Dis 2010; 30: 202.
50 De Smedt A, De Raedt S, Nieboer K et al. Intrave-
nous thrombolysis with recombinant tissue plas-
minogen activator in a stroke patient treated with
dabigatran. Cerebrovasc Dis 2010; 30: 533–4.
51 Matute MC, Guillan M, Garcia-Caldentey J et al.
Thrombolysis treatment for acute ischaemic stroke
in a patient on treatment with dabigatran. Thromb
Haemost 2011; 106: 178–9.
52 Lee VH, Conners JJ, Prabhakaran S. Intravenous
thrombolysis in a stroke patient taking dabigatran.
J Stroke Cerebrovasc Dis 2012; 21: 916.e11–2.
53 Sangha N, El Khoury R, Misra V, Lopez G. Acute
ischemic stroke treated with intravenous tissue plas-
minogen activator in a patient taking dabigatran with
radiographic evidence of recanalization. J Stroke Cere-
brovasc Dis 2012; 21: 917. e5-8.
54 Testai FD. Intravenous thrombolysis in a stroke
patient taking dabigatran. J Stroke Cerebrovasc Dis
2012; doi:10.1016/j.jstrokecerebrovasdis.2012.06.017
55 Weimar C, Hohnloser SH, Eikelboom JW, Diener
HC. Preventing cardioembolic stroke in atrial
fibrillation with dabigatran. Curr Neurol Neurosci
Rep 2012; 12: 17–23.
56 Nagarakanti R, Ezekowitz MD, Oldgren J et al.
Dabigatran versus warfarin in patients with atrial
fibrillation: an analysis of patients undergoing car-
dioversion. Circulation 2011; 123: 131–6.
57 Clemens A, Haertter S, Friedman J et al. Twice
daily dosing of dabigatran for stroke prevention in
atrial fibrillation: a pharmacokinetic justification.
Curr Med Res Opin 2012; 28: 195–201.
58 Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC.
Effect of medication dosing frequency on adherence in
chronic diseases. Am J Manag Care 2009; 15: e22–33.
59 Brown TM, Siu K, Walker D et al. Development of
a conceptual model of adherence to oral anticoagu-
lants to reduce risk of stroke in patients with atrial
fibrillation. J Manag Care Pharm 2012; 18: 351–62.
60 van Ryn J, Stangier J, Haertter S et al. Dabigatran
etexilate – a novel, reversible, oral direct thrombin
inhibitor: interpretation of coagulation assays and
reversal of anticoagulant activity. Thromb Haemost
2010; 103: 1116–27.
61 Levi MM, Eerenberg E, Lowenberg E, Kamphuisen
PW. Bleeding in patients using new anticoagulants
or antiplatelet agents: risk factors and management.
Neth J Med 2010; 68: 68–76.
62 Lakkireddy D, Reddy YM, Di Biase L et al. Feasi-
bility and safety of dabigatran versus warfarin for
periprocedural anticoagulation in patients undergo-
ing radiofrequency ablation for atrial fibrillation:
results from a multicenter prospective registry. J
Am Coll Cardiol 2012; 59: 1168–74.
63 Kaseno K, Naito S, Nakamura K et al. Efficacy and
safety of periprocedural dabigatran in patients
undergoing catheter ablation of atrial fibrillation.
Circ J 2012; 76: 2337–42.
64 Winkle RA, Mead RH, Engel G et al. Safety of da-
bigatran versus warfarin for periprocedural antico-
agulation in patients undergoing ablation for atrial
fibrillation. J Am Coll Cardiol 2012; 60: 1118–9.
65 Calkins H, Kuck KH, Cappato R et al. 2012 HRS/
EHRA/ECAS Expert Consensus Statement on Cath-
eter and Surgical Ablation of Atrial Fibrillation:
recommendations for patient selection, procedural
techniques, patient management and follow-up,
definitions, endpoints, and research trial design.
Europace 2012; 14: 528–606.
66 Kher A, Al Dieri R, Hemker HC, Beguin S. Labora-
tory assessment of antithrombotic therapy: what
tests and if so why? Haemostasis 1997; 27: 211–8.
Paper received July 2012, accepted February 2013
ª 2013 John Wiley & Sons Ltd
Int J Clin Pract, June 2013, 67, 6, 516–526
526 Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
